Efficacy and Safety of Biosimilar Cetuximab (CETUXA) in Locoregionally Advanced or Recurrent Squamous Cell Carcinoma of the Head and Neck: A Retrospective Multicenter Analysis. (2025). Journal of Carcinogenesis, 24(10s), 382-389. https://doi.org/10.64149/J.Carcinog.24.10s.382-389